Actively Recruiting
Phase II Study of BL-B01D1 Plus PD-1 Therapy for Adults With Advanced or Metastatic Urothelial Carcinoma
Led by Sichuan Baili Pharmaceutical Co., Ltd. · Updated on 2026-07-23
52
Participants Needed
1
Research Sites
78 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the efficacy and safety of a combination therapy using BL-B01D1 and PD-1 in patients with locally advanced or metastatic urothelial carcinoma, a type of bladder cancer. This is a phase II clinical study aiming to explore how well this treatment works and its safety profile in this patient group. Participants receive BL-B01D1 plus PD-1 through intravenous infusions in cycles lasting three weeks. Those showing clinical benefit may continue treatment for additional cycles. Treatment will stop if the disease progresses, if intolerable side effects occur, or for other reasons. The study focuses on assessing the treatment over up to approximately 24 months. Throughout the study, participants will be monitored for response to treatment, including tumor measurements and disease control, as well as safety through adverse event tracking. Blood samples will be collected to measure drug levels and immune responses. The main outcome measured is the objective response rate, while secondary outcomes include progression-free survival and duration of response. The total duration of participation can last up to about two years, with regular evaluations throughout this period.
CONDITIONS
Brief Title
A Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Research Team
S
Sa Xiao, PHD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here